Refocusing cancer R&D for greater impact: Addressing gaps in disparities and access

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

While cutting-edge therapies grace headlines, the impact of breakthrough research remains limited due to patient access, affordability, and adherence. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Alice L. Pomponio
Managing director, BrightEdge; Vice president, Innovation and Impact Investing, American Cancer Society
Table of Contents

YOU MAY BE INTERESTED IN

Curebound has announced eight grants for a total of $2 million in funding. The funding is made available through two new Curebound programs: Catalyst Grants, which support projects within early-stage life science companies that are seeking to take innovative discoveries to commercially approved products, and Equity Grants, which focus on overcoming disparities in cancer research and treatment in underserved populations.
Alice L. Pomponio
Managing director, BrightEdge; Vice president, Innovation and Impact Investing, American Cancer Society

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login